MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives...
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the...
MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the...
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed...
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company...
MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare...
MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has...
MELBOURNE, Australia, June 03, 2019 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today published that the...
Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food...
MELBOURNE, Australia and SINGAPORE, Dec. 19, 2018 (GLOBE NEWSWIRE) -- SUMMARY Phase II study in...
MELBOURNE, Australia, Aug. 29, 2018 (GLOBE NEWSWIRE) -- EXECUTIVE SUMMARY – FINANCIAL YEAR 01 JULY TO 30...
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- In a landmark case, the US Food and Drug...
MELBOURNE, Australia, Feb. 19, 2018 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA-DAX:UR9) (NASDAQ INTERNATIONAL...
Support
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads